These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 28465778)

  • 61. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
    Gandjour A; Ostwald DA
    Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis.
    Poulin Y; Papp KA; Wasel NR; Andrew R; Fraquelli E; Bernstein G; Chan D
    Int J Dermatol; 2010 Dec; 49(12):1368-75. PubMed ID: 21155084
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Early Intervention and Cumulative Life Course Impairment in psoriasis: a Review.
    Arancio LMH; D'Amico D; Dastoli S; Fiorella CS; Manfredini M; Moretta G; Paolino G; Levi A; Di Fino S; Zucchi B; Piaserico S
    Clin Exp Dermatol; 2024 Jul; ():. PubMed ID: 39045914
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluating the economic burden of psoriasis in the United States.
    Vanderpuye-Orgle J; Zhao Y; Lu J; Shrestha A; Sexton A; Seabury S; Lebwohl M
    J Am Acad Dermatol; 2015 Jun; 72(6):961-7.e5. PubMed ID: 25882886
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Topical steroids versus PUVA therapy in moderate plaque psoriasis: a clinical trial along with cost analysis.
    Amirnia M; Khodaeiani E; Fouladi RF; Hashemi A
    J Dermatolog Treat; 2012 Apr; 23(2):109-11. PubMed ID: 21254854
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treating pediatric plaque psoriasis: challenges and solutions.
    Thomas J; Parimalam K
    Pediatric Health Med Ther; 2016; 7():25-38. PubMed ID: 29388608
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Unmet Need in People with Psoriasis and Skin of Color in Canada and the United States.
    Yadav G; Yeung J; Miller-Monthrope Y; Lakhani O; Drudge C; Craigie S; Mendell A; Park-Wyllie L
    Dermatol Ther (Heidelb); 2022 Nov; 12(11):2401-2413. PubMed ID: 36131193
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Psoriasis: A review of systemic comorbidities and dental management considerations.
    Brooks JK
    Quintessence Int; 2018; 49(3):209-217. PubMed ID: 29335689
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The costs of psoriasis medications.
    Mustonen A; Mattila K; Leino M; Koulu L; Tuominen R
    Dermatol Ther (Heidelb); 2013 Dec; 3(2):169-77. PubMed ID: 24338674
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Living with Psoriasis Vulgaris and Multi-Treatment Failure: A Patient and Dermatologist Perspective.
    Spencer RK; Elhage KG; Jin JQ; Davis MS; Hakimi M; Bhutani T; Chang H; Liao W
    Dermatol Ther (Heidelb); 2023 Apr; 13(4):857-866. PubMed ID: 36913122
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation.
    Zozaya N; Villoro R; Abdalla F; Alfonso Zamora S; Balea Filgueiras J; Carrascosa Carrillo JM; Delgado Sánchez O; Dolz Sinisterra F; García-Ruiz A; Herranz Pinto P; Manfredi A; Martínez Olmos J; Morales de Los Ríos Luna P; Puig Sanz L; Ros S; Hildago-Vega Á
    Acta Derm Venereol; 2022 Mar; 102():adv00678. PubMed ID: 35312022
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Psoriasis causes significant economic burden to patients.
    Mustonen A; Mattila K; Leino M; Koulu L; Tuominen R
    Dermatol Ther (Heidelb); 2014 Jun; 4(1):115-24. PubMed ID: 24865468
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States.
    Greiling T; Young M; Seal MS; Higham RC; Armstrong A
    Dermatol Ther (Heidelb); 2024 Jul; 14(7):1839-1847. PubMed ID: 38874893
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician.
    Blackstone B; Patel R; Bewley A
    Psoriasis (Auckl); 2022; 12():25-33. PubMed ID: 35371967
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Psoriasis and Psoriatic Arthritis.
    Cather JC; Young M; Bergman MJ
    J Clin Aesthet Dermatol; 2017 Mar; 10(3):S16-S25. PubMed ID: 28360971
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Societal impact for patients with psoriasis: A nationwide Swedish register study.
    Häbel H; Wettermark B; Hägg D; Villacorta R; Wennerström ECM; Linder M
    JAAD Int; 2021 Jun; 3():63-75. PubMed ID: 34409373
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hit hard and early: Can the march of psoriasis be halted?
    Jandhyala S
    Indian Dermatol Online J; 2013 Jul; 4(3):177-9. PubMed ID: 23984227
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A guide to prescribing systemic treatments for psoriasis during pregnancy, breastfeeding and in those trying to conceive: what does the current evidence suggest?
    Hutchison E; Eraifej N; Moss J; Rolls S; Wainman H
    Clin Exp Dermatol; 2024 May; ():. PubMed ID: 38769610
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance.
    Kim GK; Del Rosso JQ
    J Clin Aesthet Dermatol; 2010 Jan; 3(1):32-8. PubMed ID: 20725536
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment Options in Psoriasis: Tailoring treatment to the patient's needs.
    Dantow JE
    Can Fam Physician; 1992 Apr; 38():857-988. PubMed ID: 21221381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.